The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis.

Ann MedAug 18, 2026 (epub)
Clinical ResearchOncology (Medical)Radiology (Diagnostic)Open access

Kun Liu, Youwen Zhu, Hong Zhu

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the clinical benefits of adding immune checkpoint inhibitors (ICIs) to radiotherapy in cancer patients, analyzing 15 randomized clinical trials with 7947 participants. The results indicated a pooled hazard ratio of 0.865 for overall survival and 0.799 for progression-free survival, highlighting significant improvements, particularly in non-small-cell lung and cervical cancers.

Key findings

  • Pooled HR for overall survival was 0.865 (95% CI, 0.730-1.000).
  • Pooled HR for progression-free survival was 0.799 (95% CI, 0.677-0.922).
  • In non-small-cell lung cancer, OS improved with a HR of 0.544 (0.371-0.717).
  • Adjuvant ICI therapy showed a pooled HR of 0.742 (0.649-0.834) for overall survival.

Why it matters

The findings suggest that combining immune checkpoint inhibitors with radiotherapy can enhance survival outcomes in specific cancer types, which may influence treatment strategies and improve patient management in oncology.

Source

PubMed · PMID 42613912Free full text on PubMed Central

Published in Ann Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.